Sunday , May 16 2021

The first human clinical study of HIV Drug Gammora offers a potential cure



A biotechnology company in Israel specializing in HIV and cancer treatments has finally released its first clinical study on Gammora of HIV and the news brings hope to many of the effects of this devastating retrovirus. The new drug has been detected without eliminating it 99% Inside the HIV virus four weeks treatment.

Integrations cause apoptosis

The company is called Zion Medical and Gammora is an innovative treatment consisting of a synthetic peptide compound derived from HIV-derived integra. Integraases are enzymes derived from retroviruses such as HIV that allow their genetic material to be integrated into the infected cell.

Using this process, Gammora stimulates the integration of many HIV DNA fragments into the host cell genomic DNA. This then triggers substantially the infected cell apoptosis or self-destruction.

"These first clinical outcomes were beyond our expectations and promise hope to find treatment for a disease that has been found over 35 years, "Said Dr. Esmira Naftali, Development Director, Zion Medical." Given the limited nature of this study, we are excited to prove the efficacy of our drug in step 2b, where the number of participants is longer. "

If this stage turns out to be as successful, its effects are literally life-changing. Today, current commercially available HIV antiretrovirals work by suppressing the spread of the virus, but do not provide any cure for infection.

As such, HIV patients can only hope for life-long healing, not real respite. However, the medical peptide of Zion has the potential to destroy all the cells that carry the HIV virus genome that provides a real improvement to the infected patients.

Clinical Study of Zion's Medical Phase 1 / 2a Gammora Human Study showed that most patients showed significant viral 90% from the starting level first four weeks. In Part II of the study, Gammora was further combined with additional retroviral therapies leading to patients who even showed 99% reduction of virus load from baseline four weeks.

In addition, the size 10 weeks of the tests, Gammora was found to be safe and well-tolerated. In fact, no side effects were reported.

Increasing the number of CD4 cells

In addition, Gammora was found to increase the number of CD4 cells in the patient – even 97% from the baseline. CD4 cells, also referred to as T cells or T helper cells, are cells that are killed by the HIV virus. They are white blood cells that play a central role in the human immune system, in the body's natural defense system against pathogens, infections and diseases.

As HIV infections progress, CD4 cells are significantly reduced. A person has an AIDS diagnosis when their number falls below 200 and then considered a serious risk to serious illness. For comparison, a healthy individual normal region for CD4 cells is about 500 to 1.500.

Zion Medical claims that Gammora "is designed to cope with infected HIV cells without damaging the infected cells." Its success would change the course of the HIV virus forever.


Source link